Targeted Therapeutics in Melanoma. - London | Springer Science+Business Media, LLC | 2012 - 392 Pages Includes Index

Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas – over-exposure to ultraviolet light – is well known, effective treatment has remained challenging.

The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies.

This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers.

ISBN: 978-1-61779-406-3 978-1-61779-407-0 = activation adjuvant advanced melanoma agents agonist angiogenesis anti-CTLA-4 antigen antigen-specific apoptosis autologous B-Raf bevacizumab blockade BRAF mutations cancer cells carcinoma CD4+ CD8+ T cells cell lines cell responses chemotherapy Clin Cancer Res Clin Oncol clinical response clinical trials combination cutaneous cytokines cytotoxic dacarbazine dendritic cells disease dose effector efficacy endothelial enhances function gene expression growth factor H human melanoma imatinib immune responses Immunol immunotherapy induced inhibition ipilimumab ligand lymphocytes malignant melanoma mediated MEK mela melanocytes melanoma cells melanoma patients metastatic melanoma mg/kg mice Mol molecular molecules monoclonal antibody mTOR mucosal melanoma mutations Nat noma Oncogene Oncology paclitaxel patients with metastatic peptide phase II trial potential preclinical Proc Natl Acad proliferation protein receptor regulation regulatory T cells role sorafenib specific Src STAT3 sunitinib survival T-cell target TCR temozolomide therapeutic therapy tion toxicity treatment Tregs tumor antigens tumor cells tumor microenvironment tumor-infiltrating tyrosine kinase upregulation vaccine VEGF vitro vivo Zhang.

LCCN: 2011942473

Subjects--Personal Names: --Cancer, Medical / Clinical Medicine, Medical / Oncology / General, Oncology, Electronic books, Medical / General, Melanoma -- Treatment, Medicine.